LYCOS RETRIEVER 
Asacol: Patients
built 636 days ago
Asacol may cause dizziness, drowsiness and lightheadedness. Patients are advised not to drive, operate machinery, or participate in hazardous activities while taking this drug. Using Asacol with alcohol or other medicines may alter mental alertness and performance.
Source:
Study to assess the effect on male fertility: The effect of Asacol (mesalamine) on sulfasalazine-induced impairment of male fertility was examined in an open-label study. Nine patients (age < 40 years) with chronic ulcerative colitis in clinical remission on sulfasalazine 2 g/day to 3 g/day were crossed over to an equivalent Asacol dose (0.8 g/day to 1.2 g/day) for 3 months. Improvement in sperm count (p < 0.02) and morphology (p < 0.02) occurred in all cases. Improvement in sperm motility (p < 0.001) occurred in 8 of the 9 patients.
Source:
Asacol mesalamine ; is a delayed release ph-sensitive, polymer-coated, oral preparation of 5-asa whi. Injection of doxorubicin into the eyelid may be an effective and economic permanent nonsurgical treatment for blepharospasm, hemifacial spasm, and other related facial dystonias.1-2 In studies using cynomolgus monkeys, doxorubicin treatment caused a loss of up to 70% in the number of musclefibers.3In the first clinical trial of this novel treatment protocol, 8 of 20 patients had major long-term improvement, which has now continued for up to 1 yr.4 The major drawback with the clinical use of doxorubicin chemomyectomy is the potential for eyelid skin injury as a result of the drug's toxicity. In both animal2 and patient studies, 4 skin ulceration has ocFrom the Department of Ophthalmology, University of Minnesota, Minneapolis, Minnesota. Supported by National Eye Institute Bethesda, MD ; grant EY07935, the Donald and Louise Gabbert Neuro-ophthalmology Research Fund, the Minnesota Lions and Lionesses, and an unrestricted grant to the Department of Ophthalmology from Research to Prevent Blindness, Inc. New York, NY ; . Submitted for publication: December 13, 1991; accepted April 24, 1992. Reprint requests: Linda Kirschen McLoon, PhD, Department of Ophthalmology, University of Minnesota, Box 493 UMHC, Minneapolis, MN 55455.
Source:
In a 6-month placebo-controlled maintenance trial involving 264 patients, 177 of whom were randomized to Asacol tablets, six (3.4%) of the Asacol patients discontinued Asacol therapy because of adverse events, as compared to four (4.6%) of the placebo patients. Adverse reactions leading to withdrawal from Asacol tablets included (each in one patient): anxiety; headache; pruritus; decreased libido; rheumatoid arthritis; and stomatitis and asthenia.
Source:
A total of 198 patients who received LIALDA or Asacol in the parent studies entered the maintenance phase of study 303 directly. Of these patients, 151 were in clinical and endoscopic remission, while 47 were considered well enough by their physician to receive maintenance treatment.
Source:
This analysis included data from the Asacol 2.4 g/day active control arms of these two studies. Of the 349 patients who received Asacol 2.4 g/day, 63 had isolated proctitis, 205 had left-sided disease (proctosigmoiditis and left-sided colitis) and 81 had pancolitis. To be included in the studies, patients had to have mildly to moderately active UC and a baseline score in either or both the rectal bleeding and stool frequency clinical assessments of at least 1 (based on 4-point scale, 0-3). Patients were prohibited from taking rectal therapies and were only treated with Asacol. Clinical analyses included improvement in rectal bleeding and stool frequency defined as a decrease from baseline of at least 1 point/grade. Mucosal healing was ... evaluated in patients who had a baseline endoscopy subscore of 2 or greater.
Source:
MORE ABOUT
Patients